Liquid biopsy technology company ANGLE plc (AIM: AGL) (OTCQX: ANPCY) on Wednesday announced successful results from its dual analysis of circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) using Illumina's next-generation sequencing (NGS) platform. The study, which analysed samples from 27 lung cancer patients, showed that CTC-DNA provided additional cancer biomarkers not detected in ctDNA from the same blood sample.

The results demonstrated that in untreated patients, 100% had mutations found only in CTC-DNA, while 90% of treated patients showed similar findings. Analysis of both CTC-DNA and ctDNA identified twice as many mutations, potentially offering new biomarkers for guiding cancer treatment.

ANGLE's technology, using its Parsortix system to harvest CTCs, coupled with Illumina's sequencing platform, enhances the ability to perform multiomics analysis, including RNA and protein sequencing, which is not possible with ctDNA alone. This breakthrough is expected to complement Illumina's sequencing instruments and large gene panels, further advancing the potential for CTC-based DNA analysis.

ANGLE will present these findings in a joint webinar with Illumina on 6 February 2025 at 16:00 GMT, marking the first collaborative marketing initiative between the two companies. The research aligns with ANGLE's strategy to integrate its Parsortix system with Illumina's NGS platforms for advanced cancer diagnostics.